Location: New Delhi, India
Contract: Permanent, full time position
Reporting to: India Head of Access Campaign
Application deadline: 19th August 2018
Starting date: ASAP
MSF ACCESS CAMPAIGN
Médecins Sans Frontières (MSF) is an international, independent, medical humanitarian organisation that delivers emergency aid to people affected by armed conflict, epidemics, healthcare exclusion and natural disasters. MSF offers assistance to people based only on need and irrespective of race, religion, gender or political affiliation.
Created in 1999, the Access Campaign (AC) is an MSF advocacy entity guided by MSF’s charter, and dedicated to serve MSF’s social mission. Deeply rooted in MSF’s medical operations, the AC works to tackle barriers to people’s access to medical care, ensuring that quality products such as medicines, vaccines and diagnostics are available, affordable and adapted to people in MSF projects and beyond, now and for the future. The AC is hosted by MSF International, the legal entity that binds MSF’s 21 sections, 24 associations and other offices together. Based in Geneva, MSF International provides coordination, information and support to the MSF movement, and implements international projects and initiatives as requested.
The Access Campaign’s multidisciplinary team addresses the underlying technical, legal and political barriers to developing the needed biomedical innovation and accessing existing products. While engaging in upstream systemic obstacles to access, the AC remains driven by MSF’s operational and medical priorities, balancing disease/product work and global international health policy work to ensure achievements of the AC translate into tangible benefits to MSF field interventions and beyond.
Working in close collaboration with the India Head of Access Campaign and with the technical input of the Access Campaign medical and policy team based in Europe and in the US, the Trade and IP analyst (FTAs and pharmaceuticals) will develop, support and implement advocacy strategies and activities to safeguarding public health, affordable access and innovation in trade related intellectual property negotiations.
OBJECTIVES OF THE POSITION